Onco-Innovations’ licensed technology demonstrates promise to enhance chemotherapy effectiveness by overcoming cancer cell resistance: Vancouver, BC Saturday, February 1, 2025, ...

Significant growth trajectory of the Breast Cancer Application segment, which is expected to reach US$374.1 Million by 2030 ...

The U.S. Food and Drug Administration has approved Datroway (datopotamab deruxtecan-dlnk) for adult patients with ...

Bifunctional Compositions for the Treatment of Cancer .1 This drug, which is often used to treat malaria, is being repurposed by Armaceutica, Inc. to treat various types of cancer.

Findings showed datopotamab deruxtecan reduced the risk of disease progression or death by 37% compared with chemotherapy.

Onco-Innovations Limited has announced promising results from its licensed technology of PNKP inhibitors, which enhance the ...

Enhertu (fam-trastuzumab deruxtecan-nxki) has received FDA approval for HR-positive, HER2-low, HER2-ultralow metastatic breast cancer.

Innate Pharma (IPHA) announced the first patient was dosed in its Phase 1 study, investigating the safety and tolerability of IPH4502, an ...

Efficacy of Datroway, a Trop-2-directed antibody and topoisomerase inhibitor conjugate, was determined in the TROPION-Breast01 trial of 732 patients who received Datroway or investigator’s choice of ...

Specifically, the novel Trop-2-directed antibody and topoisomerase inhibitor conjugate is indicated for those who have received prior treatment with endocrine-based therapy and chemotherapy for ...